Survival in Patients With Presymptomatic Diagnosis of Metastatic Uveal Melanoma

Authors:

Abstract
Despite excellent rates of local control of primary intraocular tumor, metastatic disease remains the leading cause of death in patients with uveal melanoma.1 Prior investigations of metastasis after proton beam irradiation for uveal melanoma revealed that the cumulative probability of metastasis at 5 years after primary treatment was 20%, with a median time to metastasis of 2.1 years after treatment.2Similarly, cumulative rates of metastasis in the Collaborative Ocular Melanoma Study3 at 5 years and 10 years after treatment were 25% and 34%, respectively. Once metastases develop, median survival is short, typically less than 1 year.4,5 The site and extent of metastases affect length of survival. Patients in whom metastases are confined to extrahepatic locations have significantly longer survival (median, 19-28 months).6 However, most patients who develop metastases have liver involvement, which results in 1-year survival of approximately 10% to 15%.6

This publication has 10 references indexed in Scilit: